Corporate Magazine 2012 - Boehringer Ingelheim

TRAJENTA® / TRADJENTA®trajenta® is a prescriptionmedicine that is used along withdiet and exercise to lowerblood sugar in adults with type 2diabetes. The once-daily tabletis used along with diet andexercise to improve glycaemiccontrol.A STRONG ALLIANCE FOR DIABETES TREATMENT OPTIONSIn January 2011, Boehringer Ingelheim and Eli Lilly and Companyhave formed an alliance in the field of diabetes that centres on fourpipeline compounds representing several of the largest treatmentclasses.We understand the ongoing need to research and develop newer,targeted medications that are specifically designed not only to provideeffective, long-term reductions in blood sugar levels but alsoavoid the limitations and tolerability issues of the current treatments.trajenta® / tradjenta® and jentadueto® are the first productsmarketed under the alliance.LIVING BETTER WITH DIABETESManaging diabetes is a life-long job for patients. Increasing awarenessabout the importance and benefits of diabetes control is thereforethe key objective of strategies for a better life with this chronic disease.Beyond our focus on drug treatments for diabetes, we are eagerto establish tools and programmes that can help patients to make lifestyleand behaviour changes.371 millionPEOPLE HAVE DIABETESAn estimated 371 million peopleworldwide have diabetes, a seriouschronic condition that occurswhen the body either does notproperly produce, or use, the hormoneinsulin.Type 2 diabetes is the most commontype, accounting for an estimated90% to 95% of all cases. Thenumber of diabetes cases is expectedto grow considerably in thecoming years due to unhealthylifestyles.Living with type 2 diabetes requiresthat patients develop a range of competenciesthat allow them to take greatercontrol over the treatment of their disease.This includes:• Education and support for selfmanagement(including reductionof lifestyle risk factors).• Effective drug treatment strategies formaintaining normal blood glucoseand lipid levels, and normal bloodpressure.• Effective surveillance for early detectionand treatment of complications.The most important aspect is that thepatients stick to a chosen regimen andproperly manage their lifestyle change.Steps towards better healthIn future, patients with certain diseases,especially chronic ones, should be treatedwith a more holistic approach beyonddrug treatment. This requires educationwith the explicit aim of enhancing activeinvolvement of patients so that they becomepartners in their healthcare process.Boehringer Ingelheim is therforeconcentrating on new business modelsand healthcare innovation.Need for educational toolsEver more patients with type 2 diabeteshave comorbidities and new treatmentsoptions have raised expectations and redefinedthe standards for treatment success.In particular, the close link betweentype 2 diabetes and the onset andprogression of nephropathy presents acommon – and often underestimatedand misunderstood – treatment challenge.In order to meet this task effectively,practitioners need answers to sev-76Boehringer Ingelheim annual report 2012